Kornimate/medical-research-clean huggingface dataset:
topical application of tranexamic acid and postoperative blood loss in femoral neck fractures

Conditions: Femoral Neck Fracture

Summary: tranexamic acid (ta) is a synthetic antifibrinolytic agent. it prevents degradation of fibrin and delays the breakdown of hemostatic clots. it has been demonstrated in multiple studies and meta analyses to decrease blood loss in elective hip and knee arthroplasty. however, concerns about the prothrombotic side effects of systemic administration of ta has hindered the widespread adoption of this medication in orthopaedic patients due to their high risk for thrombotic complications such as deep venous thrombosis and pulmonary embolism topical application of tranexamic acid has been proposed as a way to mitigate the potential prothrombotic effects of ta. topical application of ta has been demonstrated to be beneficial in oral and cardiac surgery. plasma levels of ta have been found to be minimal following topical application, minimizing its potential systemic thromboembolic side effects. ta has been used topically in total knee arthroplasty, with significant reductions in blood loss and no increase in thromboembolic complications8,10. data on the use of ta in hip fracture surgery is limited, and there are no studies examining topical use of ta in hip fracture surgery.

our study question is: does topical tranexamic acid decrease blood loss following hemiarthroplasty of the hip for femoral neck fractures? the type of information collected by the research assistant will consist of estimated blood loss during surgery, length of stay in hospital, any wound infections as well as any thromboembolic side effects (blood clots in legs and/or heart) that may occur. the number of units of red blood cells transfused will be recorded up to and including postoperative day 8. preoperative hemoglobin and lowest postoperative hemoglobin levels up to and including post-op day 8 will also be collected as well as any use of ambulatory aids will be recorded on presentation to hospital, discharge and 6 weeks post operatively.

Eligibility criteria:
inclusion criteria: * hip fracture patients * aged 65 and older. exclusion criteria: * bilateral femoral neck fracture patient and/or one that is not suited to a hemiarthroplasty repair.

Keywords: fracture hip tranexamic acid topical
research on the brain death determination in china

Conditions: Brain Death; Electroencephalogram; Evoked Potential; TCD; Quality Control

Summary: purpose china has a population of 1.4 billion and an enormous medical expenditure burden, and chinese traditional culture has a long history. it takes time to recognize and accept the concept of brain death (bd) as death. promoting brain death determination (bdd) and rationally allocating medical resources have become major national policy issues. to identify the safest and most reliable ancillary tests needed if the clinical examination is incomplete. method the technical group of the brain injury evaluation quality control center of the national health commission retrieved coma cases registered from 2013 to 2019. according to clinical criteria for brain death determination (bdd), the patients were divided into two groups: a brain-death (bd) group and a non-bd group. the bd group was divided into a complete brain death with no doubt group (bd1 group) and an incomplete brain death with doubt group (bd2 group). depending on the site of the brain injury, the accuracy of bdd was evaluated using the independent ancillary test or combined ancillary tests. data from the bqcc/nhc database and yearbook were obtained, and data analysis and status comparison were conducted on six practical activities: organizational system construction, standard and specification formulation, case quality control, professional skills training, scientific research publicity and education, and international communication.


Eligibility criteria:
inclusion criteria: * all cases met the clinical criteria for bd, involving deep coma (glasgow coma scale (gcs)=2t), the absence of brainstem reflexes (pupillary light reflex, corneal reflex, oculocephalogyric reflex, oculovestibular reflex, and cough reflex), and spontaneous respiration. ancillary tests were completed for all patients. exclusion criteria: * does not meet bd clinical evaluation criteria. ancillary tests were not implemented.
importance of cytokines in peptic ulcer disease: implications for treatment

Conditions: Peptic Ulcer

Summary: although all ppis are effective, there are some differences in their clinical performance, particularly in terms of the degree and speed of gastric acid suppression. few data are also available about their effect of the pathophysiological mechanisms of gastritis and peptic ulcer disease. aim of the present study is to investigate the effect of therapy with esomeprazole or rabeprazole on the mechanism of pathogenesis of gastritis and particularly on the pattern of release of pro- and anti- inflammatory cytokines associated to peptic ulcerative process by the gastric mucosa.

although all ppis are effective, there are some differences in their clinical performance, particularly in terms of the degree and speed of gastric acid suppression. few data are also available about their effect of the pathophysiological mechanisms of gastritis and peptic ulcer disease. triggering receptor expressed on myeloid cells (trem)-1 is a recently discovered receptor expressed on the surface of neutrophils and monocytes. engagement of trem-1 has been reported to trigger the synthesis of proinflammatory cytokines. a soluble form of trem-1, named strem-1, was observed and identified at significant levels in serum samples from patients with disease of the gastrointestinal tract inflammatory bowel disease. rendering interest about the implication of strem-1 in their pathogenesis. strem-1 was also found elevated in the gastric juice of patients with peptic ulcer disease being correlated to the degree of the infiltration of the gastric mucosa by neutrophils. published data of our group elicit that strem-1 secretion is a crucial parameter for evolution from chronic gastritis to peptic ulcer disease. samples of biopsies of gastric mucosa were cultured in the absence/presence of endotoxins showing that the inflamed mucosa was a potent secretor of strem-1 whatever ceased to exist post-antisecretory treatment. aim of the present study is to investigate the effect of therapy with esomeprazole or rabeprazole on the mechanism of pathogenesis of gastritis and particularly on the pattern of release of pro- and anti- inflammatory cytokines associated to peptic ulcerative process by the gastric mucosa.

Eligibility criteria:
inclusion criteria: * written informed consent. * abdominal pain or discomfort and/or * epigastric pain with nausea and vomiting and/or * dyspepsia. exclusion criteria: * recent upper gi bleeding * gastric carcinoma * diabetes mellitus * liver cirrhosis * acute or chronic renal failure * the ingestion of any antimicrobial or antisecretory medication for at least 15 days prior to endoscopy.

Keywords: peptic ulcer gastritis strem-1 cytokines changes of inflammatory status in gastric mucosa strem-1 as a disease marker
safety and performance of polythese® vascular prosthesis

Conditions: Aneurysm Arterial; Peripheral Arterial Disease; Marfan Syndrome; Arterial Dissections; Ehlers-Danlos Syndrome

Summary: polythese® study is a retrospective, observational, multicentre, case series which examine short and long-term outcomes of using polythese®. this study will be done on real world data to describe the safety and performance of the device. pmcf study.


Eligibility criteria:
inclusion criteria: patients must meet the following inclusion criteria in order to be eligible for inclusion in the study: - patient has a minimum of 1-year post-operative follow-up data available, or complete data to death exclusion criteria: - none
airway management and weight in children

Conditions: Perioperative Respiratory Adverse Events; Airway Management

Summary: the investigators in this study want to see how overweight/obese children who undergo elective surgery requiring airway management react to general anesthesia. they believe that the incidence of perioperative respiratory adverse events (prae) associated with laryngeal mask airway (lma) use during general anesthesia in overweight/obese children is lower than that associated with endotracheal intubation (ett).


Eligibility criteria:
inclusion criteria: * sex-specific body mass index (bmi) is ≥85th percentile * elective surgical outpatient peripheral or lower abdominal procedures * surgery length estimated to last between 30 and 120 minutes exclusion criteria: * active gastro-esophageal reflux, possible difficult intubation or planned asleep fiber optic intubation, cardiac disease, thoracic deformities, upper abdominal, and thoracic or airway surgeries. * children with active asthmatic attack or those considered to be "full stomach" will also be excluded. * laparoscopic surgical procedures and those requiring extreme head-down tilt will also be excluded. * children with a physiology or other condition requiring a certain type of airway for the procedure will also be excluded * children whose anesthesiologist is not agreeable to randomization of airway management choice will also be excluded.

Keywords: laryngeal mask airway endotracheal intubation obese
abl90 fp mc neonatal arterial, venous, capillary blood

Conditions: Congenital Heart Disease

Summary: the goal of this clinical trial is to validate performance claims for method comparison for abl90 flex plus in heparinized neonatal arterial, venous, and capillary whole blood for ctbil and fhbf in a point of care (poc) setting.

the main question it aims to answer is: to quantify the relationship using comparison measurement from the same sample between the test device and the predicate device within the reportable range for ctbil and fhbf in heparinized arterial and venous neonatal whole blood in syringe measuring mode (s65, sp65) and heparinized mixed venous/arterial whole blood samples in capillary measuring mode (c65).

Eligibility criteria:
inclusion criteria: * the following are the inclusion criteria for the neonatal subjects: * the age of the subject must be ≤28 days. * subject evaluated as suitable according to the protocol to enroll in the study by principal investigator or designee. * subjects having a sample drawn as part of standard of care that meets the requirements for samples in this study. the following are the inclusion criteria for the subjects providing placenta for cord blood: • delivery ≥38 weeks of gestation. exclusion criteria: * the following are the exclusion criteria for the neonatal subjects: * subject who has already provided successful results from arterial, venous and mixed venous/arterial samples, to cover both syringe modes and the capillary mode and parameters. * subjects exposed to the substances listed in appendix 1 with last dose within 72 hours, should be excluded due to risk of interference. * subjects with known infectious disease such as hepatitis c and hiv (in order to ensure the operator safety). the following are the exclusion criteria for the subjects providing placenta for cord blood: • subjects positive of hiv or hepatitis c

Keywords: blood gas
suprachoroidal triamcinolone acetonide in harada's retinal detachment

Conditions: Vogt Koyanagi Harada Disease

Summary: suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection

suprachoroidal injection, a novel technique for delivering ocular therapies, may facilitate targeted therapeutic delivery to the choroidal and retinal structures than intravitreal injection. yielding high levels of corticosteroid in the retinal and choroidal layers which was detectable for more than 3 months with limited exposure in the anterior segment. triamcinolone acetonide is a synthetic corticosteroid formulated as an injectable suspension and has been evaluated in a number of trials to be 7.5 fold more potent anti-inflammatory than cortisone. triamcinolone acetonide enhance tight junctions between endothelial cells thus reducing vessel leakage. it also has an angiostatic action by inhibition of vascular endothelial growth factor and has a useful effect on many inflammatory retinal diseases. the recommended dose of triamcinolone acetonide injection is 4 mg/0.1 ml which was administrated in this study. the aim of this study was to assess the efficacy of suprachoroidal triamcinolone acetonide injection (scta) as adjunctive therapy in the management of vogt-koyanagi harada's (vkh) multiple serous retinal detachment (rd) and evaluate best corrected visual acuity (bcva), intraocular pressure(iop) and central foveal thickness (cft) by optical coherence tomography (oct) in patients diagnosed as vkh at ophthalmology clinic, benha university, egypt and ebsar eye center, benha, egypt.

Eligibility criteria:
inclusion criteria: * patients diagnosed as vkh serous retinal detachment in the acute phase whom bcva is not improving after 2 weeks from starting systemic steroids. exclusion criteria: * recent intraocular surgery. * patients refuse to participate in the study. * media opacity and other causes of serous retinal detachment than vkh.

Keywords: vogt-koyanagi harada, suprachoroidal injection
s9333a study of blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia.

objectives: * determine whether calmodulin-dependent protein kinase ii-γ (camkiiγ) activation (autophosphorylation) is associated with specific clinicopathological variables and outcomes in blood and bone marrow samples from patients with previously untreated primary acute myeloid leukemia. outline: blood and bone marrow samples are analyzed by western blot using sds-page and immunoblotting using anti-calmodulin-dependent protein kinase ii-γ (camkiiγ) and anti-phosphospecific (thr286, 287) camkiiγ antibodies with signals detected via chemiluminescence. camkiiγ activation levels are linked to clinical variables within the swog database.

Eligibility criteria:
disease characteristics: * cryopreserved specimens of marrow or peripheral blood from patients enrolled in clinical trial swog-9333 and meeting the following criteria: * diagnosis of primary acute myeloid leukemia * no m3 disease * previously untreated disease * randomized to remission induction chemotherapy with mitoxantrone hydrochloride and etoposide (arm ii) patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: adult erythroleukemia (m6a) adult pure erythroid leukemia (m6b) adult acute megakaryoblastic leukemia (m7) adult acute minimally differentiated myeloid leukemia (m0) adult acute monoblastic leukemia (m5a) adult acute monocytic leukemia (m5b) adult acute myeloblastic leukemia with maturation (m2) adult acute myeloblastic leukemia without maturation (m1) adult acute myelomonocytic leukemia (m4) adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with 11q23 (mll) abnormalities untreated adult acute myeloid leukemia
trochanteric fractures - how to improve the results of reduction and implant positioning

Conditions: Hip Fractures

Summary: this prospective study (including patients with an intertrochanteric or subtrochanteric fractures type 31a1, 31a2 and 31a3) is to assess the effect of an educational intervention for operating surgeons with respect to an improvement of the quality of reduction and internal stabilisation of intertrochanteric fractures. a historic cohort of patients operated at the university hospital basel for an intertrochanteric fracture from 2014-2015 will be used for comparison.

intertrochanteric fractures are one of the most frequent fracture type in the elderly population usually occurring in patients older than 60 years of age. almost all fractures are treated operatively with reduction and stabilisation of the fracture using either a dynamic hip screw or an intramedullary nail. the reduction of the fracture and positioning of the implant are surgeon dependent factors and can be influenced by educational interventions. the investigators hypothesized that a structured educational program on the optimal use of intraoperative fluoroscopy to control the quality of reduction and the position of the implant, as well as the provision of a practical algorithm intraoperatively guiding reduction and stabilisation of intertrochanteric fractures would improve the radiologic outcome.

Eligibility criteria:
inclusion criteria: * patients presenting with an intertrochanteric fracture type 31a1 or 31a2 or subtrochanteric fracture type 31a3 * surgeon must have completed the teaching video on how to evaluate intraoperatively the fracture, the reduction and the implant positioning and complete the reduction algorithm documenting that all intraoperative steps have been correctly accomplished exclusion criteria: * patients operated without adherence to the reduction algorithm * patients operated by surgeons who did not attend the teaching session

Keywords: implant positioning reduction intraoperative fluoroscopy reduction algorithm
amlodipine/atorvastatin (caduet®) drug use investigation (regulatory post marketing commitment plan)

Conditions: Hypertension; Angina Pectoris; Hypercholesterolemia; Familial Hypercholesterolemia

Summary: in this survey, to collect the safety and efficacy information of amlodipine /atorvastatin (caduet® combination tablets) in daily medical practice will be examined. in addition, the necessity of special investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.

all the subjects whom an investigator prescribes the first amlodipine /atorvastatin (caduet®) combination tablets should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Eligibility criteria:
inclusion criteria: * male or female subjects intend to treat their cardiovascular disease who are prescribed amlodipine /atorvastatin (caduet®) combination tablets by their physicians exclusion criteria: subjects who have been prescribed amlodipine /atorvastatin (caduet®) combination tablets before.

Keywords: hypertension angina pectoris hypercholesterolemia familial hypercholesterolemia japanese caduet regulatory post marketing commitment plan
study of pxl065 in patients with nonalcoholic steatohepatitis (nash)

Conditions: NASH - Nonalcoholic Steatohepatitis

Summary: this study will assess the effect of 3 doses of pxl065 versus placebo on liver fat content in nash patients after 36 weeks of treatment

the study will be performed in patients with nash. the primary endpoint will be the assessment of the change in the percentage of liver fat content (assessed by mri-pdff).

Eligibility criteria:
inclusion criteria: * patients have given written informed consent * body mass index (bmi) ≤ 50 kg/m² * for patients with type 2 diabetes mellitus: either naive of glucose lowering drug or under stable oral glucose lowering drug * estimated glomerular filtration rate (egfr) ≥ 45 ml/min/1.73m² * liver fat content ≥ 8% on mri-pdff * qualifying liver biopsy (nas) ≥ 4 and fibrosis score f1, f2 or f3 * effective contraception for women of child bearing potential exclusion criteria: * evidence of another form of liver disease * evidence of liver cirrhosis * evidence of hepatic impairment * positive serologic evidence of current infectious liver disease * history of excessive alcohol intake * acute cardiovascular disease within 6 months prior to randomization * any disease which in the investigator's opinion which in the investigator's opinion would exclude the patient from the study * use of non-permitted concomitant medication * pregnancy or lactation
study of the risk of ischaemia following the creation of an arteriovenous fistula

Conditions: Renal Failure

Summary: the purpose of this study is to identify functional vascular changes and clinical factors correlated with the occurrence of short- or medium-term hand ischaemia after arteriovenous fistula creation.

this is a non-interventional, prospective, non-randomised, descriptive, single-centre study with no comparator. the study population will be adult patients with chronic renal failure for whom an arteriovenous fistula has been planned. patients requiring the creation of an arteriovenous fistula by the surgeons at hôpital privé des peupliers will be seen beforehand in the usual pre-operative consultation, during which the surgeon will explain the principle of the operation and the expected benefits/risks. on the day of surgery, patients will undergo the surgical procedure to create an arteriovenous fistula and will be discharged the same day. patients will be reviewed during post-operative follow-up visits at 1, 6 and 12 months as in standard practice. all the data collected in the study were collected in routine medical practice.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * stage 5 chronic kidney disease, on dialysis or not on dialysis; * requiring the creation of an arteriovenous fistula; * membership of a social insurance scheme; * patient having been informed and having formulated his/her oral non-opposition to participate in the research. exclusion criteria: * contraindication to the proposed surgery ; * reduced life expectancy in the opinion of the investigator; * medical or biological conditions which, in the opinion of the investigator, could influence the interpretation of the results of the study or the safety of the patient; * patient uncooperative with protocol requirements or unable to attend scheduled visits to the centre; * other surgical or medical intervention planned during the study; * pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding; * participating in another clinical trial, or in a period of exclusion from another clinical trial; * patient under guardianship or deprived of liberty.
multidimensional approach in patients with severe cerebral palsy, prospective cohort(mapcp cohort)-offline

Conditions: Cerebral Palsy, Spastic

Summary: in children with cerebral palsy, secondary problems lead to hip dislocation and scoliosis. but there is no definite evidence for the dislocation of hip and scoliosis. the investigators want to verify evidence of scoliosis and dislocation of hip.

observation cohort study. the investigators will measure for finding evidence by checking the x-ray photograph, hip adductor muscles pressure test and electromyography(emg test) test of hip adductor and spine muscles

Eligibility criteria:
inclusion criteria: * severe cerebral palsy patients(gmfcs level 3,4,5) * 2 to 10 years old exclusion criteria: * those who disagree with the study. * other than cerebral palsy.

Keywords: hip dislocation gmfcs level 3,4,5 scoliosis